Genomics in the land of regulatory science

Regulatory Toxicology and Pharmacology

Volumn 72, Issue 1, 2015, Pages 102-106

  Tong, Weida ^a   Ostroff, Stephen ^b   Blais, Burton ^c   Silva, Primal ^c   Dubuc, Martine ^c   Healy, Marion ^d   Slikker, William ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c CANADIAN FOOD INSPECTION AGENCY   (Canada)

^d Food Standards Australia New Zealand   (Australia)

Author keywords

Genomics; Next generation sequencing; Regulatory science

Indexed keywords

ARTICLE; BIOINFORMATICS; FOOD AND DRUG ADMINISTRATION; FOOD CONTROL; FOOD SAFETY; GENOMICS; GOVERNMENT REGULATION; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; MEDICAL DEVICE; PHARMACOGENOMICS; PRIORITY JOURNAL; PRODUCT SAFETY; PUBLIC HEALTH; RISK ASSESSMENT; STANDARDIZATION; BIOLOGY; DECISION MAKING; HUMAN; PROCEDURES; SCIENCE;

COMPUTATIONAL BIOLOGY; DECISION MAKING; FOOD SAFETY; GENOMICS; HUMANS; SCIENCE;

EID: 84926642783     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.03.008     Document Type: Article

References (12)

1. FSANZ (2013). Food Standards Australia New Zealand (FSANZ), Risk Analysis in Food Regulation.
2. Goodsaid F.M., Amur S., Aubrecht J., Burczynski M.E., Carl K., Catalano J., Charlab R., Close S., Cornu-Artis C., Essioux L., et al. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat. Rev. Drug Discov. 2010, 9:435-445.
3. Hamburg M.A. Advancing regulatory science. Science 2011, 331:987.
4. Howard P.C., Tong W., Weichold F., Healy M., Slikker W. Global summit on regulatory science. Regulatory Toxicology and Pharmacology 2013.
5. Lu J.T., Campeau P.M., Lee B.H. Genotype-phenotype correlation - promiscuity in the era of next-generation sequencing. N. Engl. J. Med. 2014, 371:593-596.
6. Miller M.A., Tong W., Fan X., Slikker W. 2012 Global Summit on Regulatory Science (GSRS-2012) - modernizing toxicology. Toxicol. Sci. 2013, 131:9-12.
7. Otsubo Y., Ishiguro A., Uyama Y. Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments. Pharmacogenomics 2013, 14:195-203.
8. Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467-470.
9. Slikker W., Ann Miller M., Lou Valdez M., Hamburg M.A. Advancing global health through regulatory science research: summary of the global summit on regulatory science research and innovation. Regul. Toxicol. Pharmacol. 2012, 62:471-473.
10. Tong W., Harris S.C., Fang H., Shi L., Perkins R., Goodsaid F., Frueh F.W. An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path Initiative. Drug Discov. Today: Technol. 2007, 4:3-8.
11. Venter J.C. The human genome at 10: successes and challenges. Science 2011, 331:546-547.
12. Woosley R.L. One hundred years of drug regulation: where do we go from here?. Annu. Rev. Pharmacol. Toxicol. 2013, 53:255-273.